Fundraising Fox

DeepCure

3 known investors

deepcure.ai ↗

DeepCure develops small molecule therapies for immune and autoimmune diseases, with pipeline candidates including an oral STAT6 inhibitor (DC-15442) and DC-9476 for conditions such as rheumatoid arthritis. The company works with academic researchers, including the Leeds Institute of Rheumatic and Musculoskeletal Medicine.

AI & Machine LearningBiotechHealthtech

Investors · 3

IAG Capital PartnersCharlestonvia Joel Whitley · inferred
The E14 FundCambridge · $1M – $5M
TLV PartnersTel Aviv · $3M – $70M

In the news

DeepCure Raises $24.6 Million in Series A-1 Round | The SaaS Newsthesaasnews.com · Apr 2024DeepCure: Small Molecule Therapeutics Company Raises $24 Millionpulse2.com · Apr 2024DeepCure Closes $24M Series A-1 Fundingfinsmes.com · Apr 2024DeepCure Closes $24M Funding Round Led by IAG Capital Partnersbusinesswire.com · Apr 2024DeepCure Closes $40M Series A Funding Led by Morningside Venturesbusinesswire.com · Nov 2021AI drug discovery co DeepCure raises $40m - Globesen.globes.co.il · Nov 2021

Frequently asked questions

What does DeepCure do?
DeepCure develops small molecule therapies for immune and autoimmune diseases, with pipeline candidates including an oral STAT6 inhibitor (DC-15442) and DC-9476 for conditions such as rheumatoid arthritis. The company works with academic researchers, including the Leeds Institute of Rheumatic and Musculoskeletal Medicine.
Who are DeepCure's investors?
DeepCure's investors include IAG Capital Partners, The E14 Fund, TLV Partners.